Systemic Iron Homeostasis, Physiological Reviews, vol.93, issue.4, pp.1721-1762, 2013. ,
DOI : 10.1152/physrev.00008.2013
URL : http://physrev.physiology.org/content/physrev/93/4/1721.full.pdf
Systemic iron homeostasis and erythropoiesis, IUBMB Life, vol.38, issue.120, pp.399-413, 2017. ,
DOI : 10.1111/ijlh.12505
Molecular regulation of cellular iron balance, IUBMB Life, vol.7, issue.6, pp.389-98, 2017. ,
DOI : 10.3389/fphar.2016.00160
Hepcidin and iron homeostasis, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1823, issue.9, pp.1434-1477, 2012. ,
DOI : 10.1016/j.bbamcr.2012.01.014
URL : https://doi.org/10.1016/j.bbamcr.2012.01.014
Hepcidin???a regulator of intestinal iron absorption and iron recycling by macrophages, Best Practice & Research Clinical Haematology, vol.18, issue.2, pp.171-82, 2005. ,
DOI : 10.1016/j.beha.2004.08.020
Hepcidin in iron overload disorders, Blood, vol.105, issue.10, pp.4103-4108, 2005. ,
DOI : 10.1182/blood-2004-12-4844
URL : http://www.bloodjournal.org/content/bloodjournal/105/10/4103.full.pdf
The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major, Haematologica. juin, vol.91, issue.6, pp.809-821, 2006. ,
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin, Nature Medicine, vol.33, issue.9, pp.1096-101, 2007. ,
DOI : 10.1016/S0167-4781(97)00122-X
Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II, Journal of Molecular Medicine, vol.115, issue.8, pp.811-817, 2011. ,
DOI : 10.1182/blood-2009-09-238105
Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I, Blood, vol.112, issue.13, pp.5241-5245, 2008. ,
DOI : 10.1182/blood-2008-06-165738
URL : http://www.bloodjournal.org/content/bloodjournal/112/13/5241.full.pdf
Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells, Blood, vol.114, issue.1, pp.181-187, 2009. ,
DOI : 10.1182/blood-2008-12-195503
Disponible sur: https://www.inserm.fr/thematiques/physiopathologie-metabolisme-nutrition/dossiers-d- information/hemochromatose-genetique, 2017. ,
pdf [Internet]. [cité 14 juill 2017] Disponible sur: https://www.orpha.net/data ,
Complications and treatment of patients with ??-thalassemia in France: results of the National Registry, Haematologica, vol.95, issue.5, pp.724-733, 2010. ,
DOI : 10.3324/haematol.2009.018051
Management of iron overload in hemoglobinopathies, Transfusion Clinique et Biologique, vol.24, issue.3, 2017. ,
DOI : 10.1016/j.tracli.2017.06.008
Sickle cell disease. The Lancet ,
URL : https://hal.archives-ouvertes.fr/inserm-00696264
Management of Sickle Cell Disease, JAMA, vol.312, issue.10, pp.1033-1081, 2014. ,
DOI : 10.1001/jama.2014.10517
Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease, N Engl J Med. 29 déc, vol.353, issue.26, pp.2769-78, 2005. ,
DOI : 10.1016/s0197-2456(97)00099-8
Erythrocyte pyruvate kinase deficiency: 2015 status report, American Journal of Hematology, vol.124, issue.9, pp.825-855, 2015. ,
DOI : 10.1016/0009-8981(75)90074-1
URL : http://onlinelibrary.wiley.com/doi/10.1002/ajh.24088/pdf
Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference, British Journal of Haematology, vol.101, issue.Suppl 3, pp.859-76, 2008. ,
DOI : 10.1111/j.1442-200X.1992.tb00947.x
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07269.x/pdf
Iron Overload in Children Who Are Treated for Acute Lymphoblastic Leukemia Estimated by Liver Siderosis and Serum Iron Parameters, PEDIATRICS, vol.111, issue.1, pp.91-97, 2003. ,
DOI : 10.1542/peds.111.1.91
Mechanisms of iron loading and toxicity, American Journal of Hematology, vol.25, issue.S12, pp.1128-1159, 2007. ,
DOI : 10.1152/ajpgi.00220.2005
URL : http://onlinelibrary.wiley.com/doi/10.1002/ajh.21075/pdf
Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines, Indian Journal of Endocrinology and Metabolism, vol.17, issue.1, pp.8-18, 2013. ,
DOI : 10.4103/2230-8210.107808
Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age, American Journal of Hematology, vol.87, issue.11, pp.283-285, 2013. ,
DOI : 10.1002/ajh.22247
Diabetes and Glucose Metabolism in Thalassemia Major: An Update, Expert Review of Hematology, vol.88, issue.2, pp.401-409, 2016. ,
DOI : 10.4081/thal.2013.s1.e18
A Significant Proportion of Thalassemia Major Patients Have Adrenal Insufficiency Detectable on Provocative Testing, Journal of Pediatric Hematology/Oncology, vol.37, issue.1, pp.54-63, 2015. ,
DOI : 10.1097/MPH.0000000000000199
Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome, PLOS ONE, vol.6, issue.8, p.172147, 2017. ,
DOI : 10.1371/journal.pone.0172147.t004
Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major, New England Journal of Medicine, vol.343, issue.5, pp.327-358, 2000. ,
DOI : 10.1056/NEJM200008033430503
Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool, Blood, vol.101, issue.11, pp.4632-4641, 2003. ,
DOI : 10.1182/blood-2002-09-2754
The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores, Blood, vol.116, issue.4, pp.537-580, 2010. ,
DOI : 10.1182/blood-2009-11-250308
Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major, New England Journal of Medicine, vol.331, issue.9, pp.567-73, 1994. ,
DOI : 10.1056/NEJM199409013310902
Magnetic-Susceptibility Measurement of Human Iron Stores, New England Journal of Medicine, vol.307, issue.27, pp.1671-1676, 1982. ,
DOI : 10.1056/NEJM198212303072703
Nuclear magnetic resonance study of iron overload in liver tissue, Magnetic Resonance Imaging, vol.3, issue.3, pp.275-82, 1985. ,
DOI : 10.1016/0730-725X(85)90357-1
How we manage iron overload in sickle cell patients, British Journal of Haematology, vol.312, issue.5, pp.703-719, 2017. ,
DOI : 10.1001/jama.2014.10517
Quality of Life Related to Oral versus Subcutaneous Iron Chelation: A Time Trade-off Study, Value in Health, vol.10, issue.6, pp.451-457, 2007. ,
DOI : 10.1111/j.1524-4733.2007.00200.x
Impact of psychosocial status and disease knowledge on deferoxamine adherence among thalassaemia major adolescents, International Journal of Nursing Practice, vol.40, issue.3, pp.265-74, 2014. ,
DOI : 10.1080/02739615.2011.537934
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with ??-thalassaemia: the ESCALATOR study, European Journal of Haematology, vol.91, issue.6, pp.458-65, 2009. ,
DOI : 10.1111/j.1600-0609.2009.01228.x
Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-na??ve children with transfusional iron overload, European Journal of Haematology, vol.87, issue.5, pp.431-439, 2012. ,
DOI : 10.1111/j.1600-0609.2011.01662.x
Current recommendations for chelation for transfusion-dependent thalassemia, Annals of the New York Academy of Sciences, vol.95, issue.1, pp.107-121, 2016. ,
DOI : 10.1111/ejh.12507
Clinical application of deferasirox: Practical patient management, American Journal of Hematology, vol.91, issue.5, pp.398-402, 2008. ,
DOI : 10.1002/ajh.21119
URL : http://onlinelibrary.wiley.com/doi/10.1002/ajh.21119/pdf
Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen, The Journal of Clinical Pharmacology, vol.509, issue.4, pp.428-463, 2008. ,
DOI : 10.1007/978-1-4615-0593-8_10
Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?, European Journal of Haematology, vol.24, issue.894, pp.310-317, 2015. ,
DOI : 10.1097/00007691-200202000-00018
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with betathalassemia major, Haematologica. oct, vol.91, issue.10, pp.1343-51, 2006. ,
A Method to Measure Deferasirox in Plasma Using HPLC Coupled With MS/MS Detection and its Potential Application, Therapeutic Drug Monitoring, vol.32, issue.4, pp.476-81, 2010. ,
DOI : 10.1097/FTD.0b013e3181d8b37f
Non-invasive assessment of tissue iron overload, Hematology, vol.2009, issue.1, 2009. ,
DOI : 10.1182/asheducation-2009.1.215
Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial, Transfusion Medicine, vol.15, issue.6, pp.389-96, 2013. ,
DOI : 10.1080/03670244.1984.9990804
Long-term safety and efficacy of deferasirox (Exjade??) for up to 5???years in transfusional iron-overloaded patients with sickle cell disease, British Journal of Haematology, vol.1, issue.Suppl. 1, pp.387-97, 2011. ,
DOI : 10.1016/j.jpeds.2005.02.030
Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST) Pediatr Blood Cancer, 2017. ,
A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires, Clinical Pharmacology & Therapeutics, vol.1, 2017. ,
DOI : 10.1186/1477-7525-1-29
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases, Gastroenterology, vol.153, issue.3, pp.835-857, 2017. ,
DOI : 10.1053/j.gastro.2017.07.031
Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to ??-Thalassemia, The Journal of Clinical Pharmacology, vol.755, issue.6, pp.565-72, 2003. ,
DOI : 10.1016/S0378-4347(01)00079-2
Clinical Pharmacology of Deferasirox, Clinical Pharmacokinetics, vol.120, issue.21, pp.679-94, 2014. ,
DOI : 10.1182/blood-2009-04-217455
Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients, Pharmacogenomics, vol.20, issue.8, pp.539-54, 2017. ,
DOI : 10.18632/oncotarget.1050
Importance of optimal dosing ???30???mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with ??-thalassaemia, European Journal of Haematology, vol.147, issue.Suppl 2, pp.355-65, 2011. ,
DOI : 10.1111/j.1365-2141.2009.07908.x
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2011.01662.x/pdf
Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study), European Journal of Haematology, vol.147, issue.11, pp.97-105, 2017. ,
DOI : 10.1111/j.1365-2141.2009.07908.x
Deferasirox-induced renal impairment in children: an increasing concern for pediatricians, Pediatric Nephrology, vol.32, issue.Suppl 2, pp.2115-2137, 2012. ,
DOI : 10.1097/MPH.0b013e3181ec0c4d
Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature, Journal of Clinical Pharmacy and Therapeutics, vol.32, issue.6, pp.526-533, 2013. ,
DOI : 10.1097/MPH.0b013e3181ec0c4d
Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer, avr, vol.56, issue.4, pp.674-680, 2011. ,
Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis, European Journal of Clinical Pharmacology, vol.30, issue.2 ,
DOI : 10.1038/clpt.1981.154
Serum hepcidin assay in 2011: where do we stand?], Ann Biol Clin août, vol.70, issue.4, pp.377-86, 2012. ,